CoChat

Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review

Open access
Alsuhaibani, Ray, Smith, Douglas Cary, Lowrie, Richard, Aljhani, Sumayah, Paudyal, Vibhu · 2021 · BMC Psychiatry

Published version of a preprint

Cited by 97

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Objective: It is estimated that up to 75% of patients with severe mental illness (SMI) also have substance use disorder (SUD). The aim of this systematic review was to explore the scope, quality and inclusivity of international clinical guidelines on mental health and/or substance abuse in relation to diagnosis and treatment of co-existing disorders and considerations for wider social and contextual factors in treatment recommendations. Method: A protocol (PROSPERO CRD42020187094) driven systematic review was conducted. A systematic search was undertaken using six databases including MEDLINE, Cochrane Library, EMBASE, PsychInfo from 2010 till June 2020; and webpages of guideline bodies and professional societies. Guideline quality was assessed based on ‘Appraisal of Guidelines for Research & Evaluation II’ (AGREE II) tool. Data was extracted using a pre-piloted structured data extraction form and synthesized narratively. Reporting was based on PRISMA guideline. Result: A total of 12,644 records were identified. Of these, 21 guidelines were included in this review. Three of the included guidelines were related to coexisting disorders, 11 related to SMI, and 7 guidelines were related to SUD. Seven (out of 18) single disorder guidelines did not adequately recommend the importance of diagnosis or treatment of concurrent disorders despite their high co-prevalence. The majority of the guidelines ( n = 15) lacked recommendations for medicines optimisation in accordance with concurrent disorders (SMI or SUD) such as in the context of drug interactions. Social cause and consequence of dual diagnosis such as homelessness and safeguarding and associated referral pathways were sparsely mentioned. Conclusion: Despite very high co-prevalence, clinical guidelines for SUD or SMI tend to have limited considerations for coexisting disorders in diagnosis, treatment and management. There is a need to improve the scope, quality and inclusivity of guidelines to offer person-centred and integrated care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-021-03188-0

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 49

  1. Carrà G, Bartoli F, Brambilla G, Crocamo C, Clerici M. Comorbid addiction and major mental illness in Europe: a narrative review. Subst Abus. 2015;36(1):75–81. https://doi.org/10.1080/08897077.2014.960551. · DOI
  2. Fantuzzi C, Mezzina R. Dual diagnosis: a systematic review of the organization of community health services. Int J Soc Psychiatry. 2020;66(3):300–10. https://doi.org/10.1177/0020764019899975. · DOI · Paper page
  3. McCreadie RG. Use of drugs, alcohol and tobacco by people with schizophrenia: case–control study. Br J Psychiatry. 2002;181(4):321–5. https://doi.org/10.1192/bjp.181.4.321. · DOI · Paper page
  4. Temmingh HS, Williams T, Siegfried N, Stein DJ. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Cochrane Database Syst Rev. 2018;1. · DOI
  5. Elliott I. Poverty and mental health: a review to inform the Joseph Rowntree Foundation’s Anti-Poverty Strategy. Available from: http://www.patient.co.uk/doctor/Poverty-and-Mental-Health.htm. Accessed 07 Feb 2021.
  6. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry. 2006;189(3):229–34. https://doi.org/10.1192/bjp.bp.105.017236. · DOI · Paper page
  7. Brunette MF, Mueser KT, Drake RE. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev. 2004;23(4):471–81. https://doi.org/10.1080/09595230412331324590. · DOI · Paper page
  8. Lambert-Harris C, Saunders EC, McGovern MP, Xie H. Organizational capacity to address co-occurring substance use and psychiatric disorders: assessing variation by level of care. J Addict Med. 2013;7(1):25–32. https://doi.org/10.1097/ADM.0b013e318276e7a4. · DOI
  9. Hjorthøj C, Østergaard MLD, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, et al. Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry. 2015;2(9):801–8. https://doi.org/10.1016/S2215-0366(15)00207-2. · DOI · Paper page
  10. Lynskey MT, Kimber J, Strang J. Drug-related mortality in psychiatric patients. Lancet Psychiatry. 2015;2(9):767–9. https://doi.org/10.1016/S2215-0366(15)00372-7. · DOI
  11. Fridell M, Bäckström M, Hesse M, Krantz P, Perrin S, Nyhlén A. Prediction of psychiatric comorbidity on premature death in a cohort of patients with substance use disorders: a 42-year follow-up. BMC Psychiatry. 2019;19(1):150. https://doi.org/10.1186/s12888-019-2098-3. · DOI
  12. Fekadu W, Mihiretu A, Craig TKJ, Fekadu A. Multidimensional impact of severe mental illness on family members: systematic review. BMJ Open. 2019;9(12). · DOI · Paper page
  13. Lukasiewicz M, Blecha L, Falissard B, Neveu X, Benyamina A, Reynaud M, et al. Dual diagnosis: prevalence, risk factors, and relationship with suicide risk in a nationwide sample of French prisoners. Alcohol Clin Exp Res. 2009;33(1):160–8. https://doi.org/10.1111/j.1530-0277.2008.00819.x. · DOI
  14. Polcin DL. Co-occurring substance abuse and mental health problems among homeless persons: suggestions for research and practice. J Soc Distress Homeless. 2016;25(1):1–10. https://doi.org/10.1179/1573658X15Y.0000000004. · DOI
  15. Schütz C, Choi F, Jae Song M, Wesarg C, Li K, Krausz M. Living with dual diagnosis and homelessness: marginalized within a marginalized group. J Dual Diagn. 2019;15(2):88–94. https://doi.org/10.1080/15504263.2019.1579948. · DOI
  16. Buckley PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. J Clin Psychiatry. 2006;67:5. · DOI · Paper page
  17. McLeod KE, Butler A, Young JT, Southalan L, Borschmann R, Sturup-Toft S, et al. Global prison health care governance and health equity: a critical lack of evidence. Am J Public Health. 2020;110(3):303–8. https://doi.org/10.2105/AJPH.2019.305465. · DOI
  18. Gunner E, Chandan SK, Yahyouche A, Paudyal V, Marwick S, Saunders K, et al. Provision and accessibility of primary healthcare services for people who are homeless: a qualitative study of patient perspectives in the UK. Br J Gen Pract. 2019;69(685):E526–36. https://doi.org/10.3399/bjgp19X704633. · DOI
  19. Paudyal V, Maclure K, Forbes-McKay K, McKenzie M, McLeod J, Smith ASD. If I die, I die, I don’t care about my health’: perspectives on self-care of people experiencing homelessness. Health Soc Care Community. 2020;28(1):160–72. https://doi.org/10.1111/hsc.12850. · DOI
  20. Paudyal V, MacLure K, Buchanan C, Wilson L, Macleod J, Stewart D. ‘When you are homeless, you are not thinking about your medication, but your food, shelter or heat for the night’: behavioural determinants of homeless patients’ adherence to prescribed medicines. Public Health. 2017;148:1–8. https://doi.org/10.1016/j.puhe.2017.03.002. · DOI
  21. Pinderup P. Challenges in working with patients with dual diagnosis. Adv Dual Diagn. 2018;11(2):60–75. https://doi.org/10.1108/ADD-11-2017-0021. · DOI
  22. Sorsa M, Greacen T, Lehto J, Åstedt-Kurki P. A qualitative study of barriers to care for people with co-occurring disorders. Arch Psychiatr Nurs. 2017;31(4):399–406. https://doi.org/10.1016/j.apnu.2017.04.013. · DOI
  23. Ducharme LJ, Knudsen HK, Roman PM. Availability of integrated care for co-occurring substance abuse and psychiatric conditions. Community Ment Health J. 2006;42(4):363–75. https://doi.org/10.1007/s10597-005-9030-7. · DOI
  24. Stewart SH, Conrod PJVO-19. State-of-the-art in cognitive-behavioral interventions for substance use disorders: introduction to the special issue. J Cogn Psychother. 2005;19(3):195.
  25. Perron BE, Bunger A, Bender K, Vaughn MG, Howard MO. Treatment guidelines for substance use disorders and serious mental illnesses: do they address co-occurring disorders? Subst Use Misuse. 2010;45(7–8):1262–78. https://doi.org/10.3109/10826080903442836. · DOI
  26. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed1000097. · doi:10.1371/journal.pmed1000097
  27. Mclellan AT. Substance misuse and substance use disorders: why do they matter in healthcare? Trans Am Clin Climatol Assoc. 2017;128:112.
  28. Brouwers MC, Kerkvliet K, Spithoff K, Consortium ANS. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. BMG. 2016;352:i1152.
  29. National Institute for Health and Care Excellence (NICE). Psychosis with coexisting substance misuse: assessment and management in adults and young people. Available from: https://www.ncbi.nlm.nih.gov/books/NBK109783/pdf/Bookshelf_NBK109783.pdf. Accessed 07 Feb 2021.
  30. Soyka M, Kranzler HR, Hesselbrock V, Kasper S, Mutschler J, Möller HJ. Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision. World J Biol Psychiatry. 2017;18(2):86–119. https://doi.org/10.1080/15622975.2016.1246752. · DOI · Paper page
  31. Preuss UW, Gouzoulis-Mayfrank E, Havemann-Reinecke U, Schäfer I, Beutel M, Hoch E, et al. Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines. Eur Arch Psychiatry Clin Neurosci. 2018;268(3):219–29. https://doi.org/10.1007/s00406-017-0801-2. Accessed 07 Feb 2021. · DOI
  32. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 3: update 2015 management of special circumstances: depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16(3):142–70. https://doi.org/10.3109/15622975.2015.1009163. · DOI · Paper page
  33. Castle DJ, Galletly CA, Dark F, Humberstone V, Morgan VA, Killackey E, et al. The 2016 royal australian and New Zealand college of psychiatrists guidelines for the management of schizophrenia and related disorders. Med J Aust. 2017;206(11):501–5. https://doi.org/10.5694/mja16.01159. · DOI
  34. Barnes TRE, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3–78. https://doi.org/10.1177/0269881119889296. · DOI · Paper page
  35. Mok YM, Chan HN, Chee KS, Chua T-E, Lim BL, Marziyana AR, et al. MOH clinical practice guidelines: bipolar disorder. Ministry of Health. Available from: https://pubmed.ncbi.nlm.nih.gov/22159936/. Accessed 07 Feb 2021.
  36. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes TRH, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553. https://doi.org/10.1177/0269881116636545. · DOI · Paper page
  37. Keating D, McWilliams S, Schneider I, Hynes C, Cousins G, Strawbridge J, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881. https://doi.org/10.1136/bmjopen-2016-013881. · DOI · Paper page
  38. Johnston A, Hsieh S-C, Carrier M, Kelly SE, Bai Z, Skidmore B, et al. A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: implications for research and policy decision-making. PLoS One. 2018;13(11):e0207410. https://doi.org/10.1371/journal.pone.0207410. · DOI
  39. Zhang P, Lu Q, Li H, Wang W, Li G, Si L, et al. The quality of guidelines for diabetic foot ulcers: a critical appraisal using the AGREE II instrument. PLoS One. 2019;14(9):e0217555. https://doi.org/10.1371/journal.pone.0217555. · DOI
  40. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005;11(5):315–39. https://doi.org/10.1097/00131746-200509000-00005. · DOI · Paper page
  41. Morrens M, Dewilde B, Sabbe B, Dom G, De Cuyper R, Moggi F. Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder. Eur Addict Res. 2011;17(3):154–63. https://doi.org/10.1159/000324480. · DOI · Paper page
  42. Bowen M, Marshall T, Yahyouche A, Paudyal V, Marwick S, Saunders K, et al. Multimorbidity and emergency department visits by a homeless population: a database study in specialist general practice. Br J Gen Pract. 2019;69(685):E515–25. https://doi.org/10.3399/bjgp19X704609. · DOI
  43. Moxley VBA, Hoj TH, Novilla MLB. Predicting homelessness among individuals diagnosed with substance use disorders using local treatment records. Addict Behav. 2020;102:106160. https://doi.org/10.1016/j.addbeh.2019.106160. · DOI
  44. Field G. Continuity of offender treatment for substance use disorders from institution to community: treatment improvement protocol (TIP) series 30. Washington, DC: Department of Health and Human Services; 1998.
  45. Paudyal V, Gibson Smith K, MacLure K, Forbes-McKay K, Radley A, Stewart D. Perceived roles and barriers in caring for the people who are homeless: a survey of UK community pharmacists. Int J Clin Pharm. 2019;41(1):215–27. https://doi.org/10.1007/s11096-019-00789-4. · DOI
  46. Jagpal P, Saunders K, Plahe G, Russell S, Barnes N, Lowrie R, et al. Research priorities in healthcare of persons experiencing homelessness: outcomes of a national multi-disciplinary stakeholder discussion in the United Kingdom. Int J Equity Health. 2020;19(1):1–7 https://doi.org/10.1186/s12939-020-01206-3. · DOI
  47. Jagpal P, Barnes N, Lowrie R, Banerjee A, Paudyal V. Clinical pharmacy intervention for persons experiencing homelessness: evaluation of patient perspectives in service design and development. Pharmacy. 2019;7(4):153. https://doi.org/10.3390/pharmacy7040153. · DOI
  48. Alenezi A, Yahyouche A, Paudyal V. Interventions to optimize prescribed medicines and reduce their misuse in chronic non-malignant pain: a systematic review. Eur J Clin Pharmacol. 2021;77(4):467–90. · DOI
  49. Ali RA, Jalal Z, Paudyal V. Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs: a systematic review. BMC Psychiatry. 2020;20(1) https://doi.org/10.1186/s12888-020-02990-6. · DOI

Cited by

See all 97

Metadata

Authors
Alsuhaibani, R., Smith, D. C., Lowrie, R., Aljhani, S., & Paudyal, V.
Venue
BMC Psychiatry
Published
2021-04-23
Volume
21
Issue
1
Pages
209-209
ISSN
1471-244X (ISSN-L)
OpenAlex
W3155073635
Cited by
97
References
10
FWCI
3.48
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. https://app.cochat.ai/papers/10.1186/s12888-021-03188-0
The paper
Alsuhaibani, R., Smith, D. C., Lowrie, R., Aljhani, S., & Paudyal, V. (2021). Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. BMC Psychiatry. https://doi.org/10.1186/s12888-021-03188-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.